期刊
CELL
卷 179, 期 2, 页码 312-339出版社
CELL PRESS
DOI: 10.1016/j.cell.2019.09.001
关键词
-
资金
- Alzheimer's Association [AACSF-18-564776]
- NIH [NS090934, AG047644, NS074969]
- Tau consortium
- JPB Foundation
- Cure Alzheimer's Fund
Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular beta-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphylated tau as neurofibrillary tangles remaim. the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clinical trials have failed to demonstrate benefits. Here, we review recent advances in our understanding of AD pathobiology and discuss current treatment strategies, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据